NASDAQ:PRAH - PRA Health Sciences Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $106.31 -1.73 (-1.60 %) (As of 03/22/2019 10:15 AM ET)Previous Close$108.04Today's Range$105.57 - $107.6652-Week Range$79.20 - $121.98Volume88,571 shsAverage Volume598,831 shsMarket Capitalization$6.97 billionP/E Ratio27.05Dividend YieldN/ABeta1.12 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email PRA Health Sciences, Inc., a contract research organization, provides outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services. It also provides strategic solutions, such as embedded, functional services provider, staff augmentation, and custom-built development solutions, as well as commercialization services; and early development services for Phase I and Phase IIa studies, and bioanalytical analysis. The Data Solutions segment offers data, analytics, technology, and consulting solutions to the life sciences market. Its services include market intelligence services, such as targeting and compensation, and pharmaceutical audit suite services; consulting and services comprising brand analytics, managed markets, commercial effectiveness, and scientific studies/clinical hubs; and technology-enabled products and services. PRA Health Sciences, Inc. conducts clinical trials in the areas of pharmaceutical development, including oncology, immunology, central nervous system, inflammation, respiratory, cardio metabolic, and infectious diseases. The company was formerly known as PRA Global Holdings, Inc. and changed its name to PRA Health Sciences, Inc. in July 2014. PRA Health Sciences, Inc. was founded in 1976 and is headquartered in Raleigh, North Carolina. Receive PRAH News and Ratings via Email Sign-up to receive the latest news and ratings for PRAH and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Commercial physical research Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PRAH Previous Symbol CUSIPN/A CIK1613859 Webwww.prahs.com Phone919-786-8200Debt Debt-to-Equity Ratio1.03 Current Ratio0.87 Quick Ratio0.87Price-To-Earnings Trailing P/E Ratio27.05 Forward P/E Ratio23.01 P/E Growth1.56 Sales & Book Value Annual Sales$2.87 billion Price / Sales2.43 Cash Flow$5.8093 per share Price / Cash Flow18.30 Book Value$16.18 per share Price / Book6.57Profitability EPS (Most Recent Fiscal Year)$3.93 Net Income$153.90 million Net Margins5.36% Return on Equity26.55% Return on Assets8.04%Miscellaneous Employees16,400 Outstanding Shares65,530,000Market Cap$6.97 billion Next Earnings Date4/24/2019 (Estimated) OptionableOptionable PRA Health Sciences (NASDAQ:PRAH) Frequently Asked Questions What is PRA Health Sciences' stock symbol? PRA Health Sciences trades on the NASDAQ under the ticker symbol "PRAH." How were PRA Health Sciences' earnings last quarter? PRA Health Sciences Inc (NASDAQ:PRAH) issued its quarterly earnings results on Wednesday, October, 31st. The medical research company reported $1.13 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $1.07 by $0.06. The medical research company earned $717.60 million during the quarter, compared to analyst estimates of $729.63 million. PRA Health Sciences had a return on equity of 26.55% and a net margin of 5.36%. The company's revenue was up 23.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.88 earnings per share. View PRA Health Sciences' Earnings History. When is PRA Health Sciences' next earnings date? PRA Health Sciences is scheduled to release their next quarterly earnings announcement on Wednesday, April 24th 2019. View Earnings Estimates for PRA Health Sciences. What guidance has PRA Health Sciences issued on next quarter's earnings? PRA Health Sciences updated its FY19 earnings guidance on Wednesday, February, 27th. The company provided earnings per share guidance of $4.93-5.08 for the period, compared to the Thomson Reuters consensus EPS estimate of $4.92. The company issued revenue guidance of $3.09-3.20 billion, compared to the consensus revenue estimate of $3.18 billion.PRA Health Sciences also updated its Q1 guidance to $1.05-1.10 EPS. What price target have analysts set for PRAH? 8 brokerages have issued 1-year price targets for PRA Health Sciences' shares. Their forecasts range from $100.00 to $122.00. On average, they expect PRA Health Sciences' share price to reach $114.25 in the next twelve months. This suggests a possible upside of 7.5% from the stock's current price. View Analyst Price Targets for PRA Health Sciences. What is the consensus analysts' recommendation for PRA Health Sciences? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PRA Health Sciences in the last year. There are currently 3 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for PRA Health Sciences. Has PRA Health Sciences been receiving favorable news coverage? Media stories about PRAH stock have been trending somewhat positive recently, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. PRA Health Sciences earned a coverage optimism score of 0.8 on InfoTrie's scale. They also gave headlines about the medical research company a news buzz of 7.0 out of 10, meaning that recent media coverage is likely to have an effect on the company's share price in the immediate future. Who are some of PRA Health Sciences' key competitors? Some companies that are related to PRA Health Sciences include Incyte (INCY), EXACT Sciences (EXAS), Icon (ICLR), Exelixis (EXEL), Charles River Laboratories Intl. (CRL), Syneos Health (SYNH), BTG (BTGGF), Medpace (MEDP), Intrexon (XON), Eloxx Pharmaceuticals (ELOX), Sorrento Therapeutics (SRNE), STARPHARMA HOLD/S (SPHRY), Pieris Pharmaceuticals (PIRS), Anavex Life Sciences (AVXL) and Luna Innovations (LUNA). What other stocks do shareholders of PRA Health Sciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other PRA Health Sciences investors own include Alibaba Group (BABA), NVIDIA (NVDA), General Electric (GE), Twitter (TWTR), Mattel (MAT), Veeva Systems (VEEV), Ultra Clean (UCTT), Paypal (PYPL), Adobe (ADBE) and Chevron (CVX). Who are PRA Health Sciences' key executives? PRA Health Sciences' management team includes the folowing people: Mr. Colin Shannon, Pres, CEO & Chairman of Directors (Age 60)Mr. Michael J. Bonello, Exec. VP & CFOMr. Kent Thoelke, Exec. VP & Chief Scientific OfficerChristine Rogers, Director of PR & Corp. CommunicationsMr. Patrick R. Spine, VP of HR When did PRA Health Sciences IPO? (PRAH) raised $306 million in an initial public offering on Thursday, November 13th 2014. The company issued 17,000,000 shares at a price of $18.00 per share. Jefferies, Citigroup, KKR, UBS Investment Bank, Credit Suisse and Wells Fargo Securities served as the underwriters for the IPO and Baird and William Blair were co-managers. Who are PRA Health Sciences' major shareholders? PRA Health Sciences' stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (9.48%), FMR LLC (3.98%), Bank of New York Mellon Corp (3.37%), Eagle Asset Management Inc. (1.64%), Pendal Group Ltd (1.36%) and Frontier Capital Management Co. LLC (1.34%). Company insiders that own PRA Health Sciences stock include Colin Shannon, David W Dockhorn, Linda Baddour, Matthew P Young and Pra Investors LP Kkr. View Institutional Ownership Trends for PRA Health Sciences. Which major investors are selling PRA Health Sciences stock? PRAH stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Acadian Asset Management LLC, Swedbank, Bank of America Corp DE, Los Angeles Capital Management & Equity Research Inc., Vaughan Nelson Investment Management L.P., Gotham Asset Management LLC and Mitchell Capital Management Co.. View Insider Buying and Selling for PRA Health Sciences. Which major investors are buying PRA Health Sciences stock? PRAH stock was bought by a variety of institutional investors in the last quarter, including Pendal Group Ltd, Standard Life Aberdeen plc, Norges Bank, Millennium Management LLC, Prudential Financial Inc., FMR LLC, First Trust Advisors LP and Frontier Capital Management Co. LLC. View Insider Buying and Selling for PRA Health Sciences. How do I buy shares of PRA Health Sciences? Shares of PRAH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is PRA Health Sciences' stock price today? One share of PRAH stock can currently be purchased for approximately $106.31. How big of a company is PRA Health Sciences? PRA Health Sciences has a market capitalization of $6.97 billion and generates $2.87 billion in revenue each year. The medical research company earns $153.90 million in net income (profit) each year or $3.93 on an earnings per share basis. PRA Health Sciences employs 16,400 workers across the globe. What is PRA Health Sciences' official website? The official website for PRA Health Sciences is http://www.prahs.com. How can I contact PRA Health Sciences? PRA Health Sciences' mailing address is 4130 PARKLAKE AVENUE SUITE 400, RALEIGH NC, 27612. The medical research company can be reached via phone at 919-786-8200 or via email at [email protected] MarketBeat Community Rating for PRA Health Sciences (NASDAQ PRAH)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 292 (Vote Outperform)Underperform Votes: 248 (Vote Underperform)Total Votes: 540MarketBeat's community ratings are surveys of what our community members think about PRA Health Sciences and other stocks. Vote "Outperform" if you believe PRAH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PRAH will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/22/2019 by MarketBeat.com StaffFeatured Article: How are Outstanding Shares Different from Authorized Shares?